(Q34257771)

31 July 2017

Diagnosing the decline in pharmaceutical R&D efficiency (English)

1 reference

31 July 2017

1 reference

1 reference

Jack W Scannell

1

1 reference

31 July 2017

Alex Blanckley

series ordinal

2

1 reference

31 July 2017

Helen Boldon

series ordinal

3

1 reference

31 July 2017

Brian Warrington

series ordinal

4

1 reference

31 July 2017

1 March 2012

1 reference

Nature Reviews Drug Discovery

31 July 2017

1 reference

31 July 2017

11

1 reference

31 July 2017

191-200

1 reference

31 July 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd3681

31 July 2017

0 references

cites work

Combinatorial chemistry in drug discovery

1 reference

Combinatorial compound libraries for drug discovery: an ongoing challenge

31 March 2020

1 reference

Historical overview of chemical library design

31 March 2020

1 reference

Sequences, sequences, and sequences

31 March 2020

1 reference

Nucleotide sequence of bacteriophage φX174 DNA

31 March 2020

1 reference

High-throughput crystallography for structural genomics

31 March 2020

1 reference

The future of high-throughput screening

31 March 2020

1 reference

Estimating the effects of regulation on innovation: an international comparative analysis of the pharmaceutical industry

31 March 2020

1 reference

A closer look at the returns and risk of pharmaceutical R&D

31 March 2020

1 reference

The productivity crisis in pharmaceutical R&D.

31 March 2020

1 reference

Can the pharmaceutical industry reduce attrition rates?

31 March 2020

1 reference

Trends in risks associated with new drug development: success rates for investigational drugs

31 March 2020

1 reference

How to improve R&D productivity: the pharmaceutical industry's grand challenge

31 March 2020

1 reference

Lessons from 60 years of pharmaceutical innovation

31 March 2020

1 reference

Rethinking clinical trials: biology's mysteries

31 March 2020

1 reference

Pharmaceutical R&D: the road to positive returns

31 March 2020

1 reference

The case for entrepreneurship in R&D in the pharmaceutical industry

31 March 2020

1 reference

Mission possible: managing innovation in drug discovery

31 March 2020

1 reference

Realism in drug discovery-could Cassandra be right?

31 March 2020

1 reference

Innovation in the pharmaceutical industry

31 March 2020

1 reference

Modern biomedical research: an internally self-consistent universe with little contact with medical reality?

31 March 2020

1 reference

Why has R&D productivity declined in the pharmaceutical industry?

31 March 2020

1 reference

Rise and fall of modern medicine

31 March 2020

1 reference

Can we rationally design promiscuous drugs?

31 March 2020

1 reference

31 March 2020

Identifying R&D outliers

1 reference

Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000

31 March 2020

1 reference

The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982-2001.

31 March 2020

1 reference

31 March 2020

1 reference

The druggable genome: an update

31 March 2020

1 reference

How many drug targets are there?

31 March 2020

1 reference

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

31 March 2020

1 reference

The slowing of treatment discovery, 1965-1995.

31 March 2020

1 reference

What went right: why is HIV a treatable infection?

31 March 2020

1 reference

31 March 2020

A dearth of new drugs

1 reference

31 March 2020

1 reference

31 March 2020

Networking for new drugs

1 reference

Multicomponent therapeutics for networked systems

31 March 2020

1 reference

A guide to drug discovery: The role of the medicinal chemist in drug discovery — then and now

31 March 2020

1 reference

How were new medicines discovered?

31 March 2020

1 reference

Probabilities of success for antibody therapeutics

31 March 2020

1 reference

Drug innovation--what's slowing it down?

31 March 2020

1 reference

Shattuck lecture--medical and societal consequences of the Human Genome Project.

31 March 2020

1 reference

Post-genome integrative biology: so that's what they call clinical science

31 March 2020

1 reference

Rethinking clinical trials

31 March 2020

1 reference

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

31 March 2020

1 reference

PARP inhibitors stumble in breast cancer

31 March 2020

1 reference

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

31 March 2020

1 reference

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

31 March 2020

1 reference

Regulatory watch: leading hedgehog inhibitor submitted for approval as skin cancer drug

31 March 2020

1 reference

The major role of clinicians in the discovery of off-label drug therapies

31 March 2020

1 reference

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

31 March 2020

1 reference

Impact of high-throughput screening in biomedical research

31 March 2020

1 reference

The art and practice of structure-based drug design: A molecular modeling perspective

31 March 2020

1 reference

Future pathways for combinatorial chemistry

31 March 2020

1 reference

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

31 March 2020

1 reference

Probing the links between in vitro potency, ADMET and physicochemical parameters.

31 March 2020

1 reference

Collective dynamics of 'small-world' networks

31 March 2020

1 reference

Rebuilding the R&D engine in big pharma.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22378269

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Next-generation sequencing for cancer diagnostics: a practical perspective.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22378269

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Escherichia coli mutants lacking all possible combinations of eight penicillin binding proteins: viability, characteristics, and implications for peptidoglycan synthesis.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22378269

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRD3681

1 reference

31 July 2017

1 reference